Recursion Pharmaceuticals Summit Therapeutics: 2026 Insight
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Looking for reliable websites to aid your investment learning? Check out our curated list of resources that support new investors on their journey.
28,161 articlesTwo biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Microsoft's stock has faced a meaningful pullback this year. This article unpacks the factors behind the drop, evalua...
A 6% weekly pullback can feel painful, but for patient buyers, this growth stock march story is about resilience, rev...
A practical guide to interpreting Champions Oncology earnings. We break down the numbers, trends, and what to watch n...
Rivian’s April milestone could reshape its growth path. This article breaks down why April could huge for Rivian, wha...
As Flotek prepares for its Q3 2025 earnings, investors will parse management tone, margins, and guidance. This articl...
Beyond Meat (BYND) 2026 unfolds with a mix of top-line growth and cost discipline. This analysis breaks down Q1 resul...
Regulatory clarity is on the horizon for digital assets as the Clarity Act advances. This guide breaks down three key...
A major AI data center deal helped IREN stock pop today, signaling potential upside beyond a single headline. This gu...
Nvidia leads the AI chip race, but AMD has momentum and strategic wins. This guide breaks down who is the better arti...
Tech optimism propelled the stock market today as inflation fears cooled and megacap tech names delivered. This snaps...
AMD stock soared in May as AI-driven demand, data center expansion, and a refreshed product lineup converged to lift ...